| Literature DB >> 24405683 |
Brian G Bell1, Francois Schellevis, Ellen Stobberingh, Herman Goossens, Mike Pringle.
Abstract
BACKGROUND: Greater use of antibiotics during the past 50 years has exerted selective pressure on susceptible bacteria and may have favoured the survival of resistant strains. Existing information on antibiotic resistance patterns from pathogens circulating among community-based patients is substantially less than from hospitalized patients on whom guidelines are often based. We therefore chose to assess the relationship between the antibiotic resistance pattern of bacteria circulating in the community and the consumption of antibiotics in the community.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24405683 PMCID: PMC3897982 DOI: 10.1186/1471-2334-14-13
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Explanatory variables
| Outcome | Positive | 164 (67%) |
| Negative or equivocal | 79 (33%) | |
| Level of sampling | Individual | 72 (30%) |
| Region/Country | 124 (51%) | |
| Other | 47 (19%) | |
| Level of analysis | Individual | 178 (73%) |
| Region/Country | 53 (22%) | |
| Other | 12 (5%) | |
| Children/Adults | Children | 88 (36%) |
| Adults | 62 (26%) | |
| Both | 93 (38%) | |
| Bacteria* | 132 (54%) | |
| 50 (21%) | ||
| Enteric Bacteria | 69 (28%) | |
| 24 (10%) | ||
| Other | 17 (7%) | |
| Most common bacteria/Drug combinations** | 104 (43%) | |
| Macrolide resistant | 56 (23%) | |
| Quinolone resistant | 41 (17%) | |
| 35 (14%) | ||
| Sulphonamide resistant | 31 (13%) | |
| Methicillin-resistant | 38 (16%) | |
| Most common antibiotics consumed*** | 132 (54%) | |
| Macrolides | 93 (38%) | |
| Sulphonamides | 59 (24%) | |
| Quinolones | 52 (21%) | |
| Antibiotic not specified | 65 (27%) | |
| Time between consumption and resistance^ | Six months or less | 129 (53%) |
| More than 6 months | 57 (23%) | |
| Same time | 43 (18%) | |
| Not specified | 14 (6%) | |
| How antibiotic consumption was assessed# | Self report | 99 (41%) |
| Medical records | 92 (38%) | |
| Sales/Prescriptions | 65 (27%) | |
| Direct application of antibiotic | 14 (6%) | |
| Region where study was conducted## | Northern Europe | 66 (27%) |
| Southern Europe | 45 (18%) | |
| US | 67 (28%) | |
| Other | 61 (25%) | |
| Type of study | Cross-sectional | 101 (42%) |
| Ecological | 56 (23%) | |
| Case–control | 35 (14%) | |
| Quasi-experiment | 21 (9%) | |
| Other | 30 (12%) | |
*Percentages do not equal 100% as any given study may have examined more than one type of bacteria.
**Percentage do not equal 100% as any given study may have examined more than one combination; resistant and non-susceptible strains of S pneumonia are combined under the resistant label for this bacterium.
***Percentages do not equal 100% as any given study may have examined more than one antibiotic.
^This variable represents the maximum time interval in any given study between when consumption occurred and resistance was measured. Studies classified as ‘same time’ tended to be ecological studies where the precise interval separating consumption and resistance could not be determined, these studies often simply reported consumption and resistance occurring together over some multi-year interval.
#Percentages do not equal 100% as any given study may have used more than one method.
##The total equals 239 as three studies were conducted in both southern Europe and northern Europe and one study was coded as not applicable.
Figure 1How studies were selected.
Figure 2Forest plot showing odds ratio and 95% confidence interval for each study along with study weight.
Figure 3Funnel plot showing effect size (odds ratio) as a function of sample size (natural log of standard error).
Weighted correlations between odds ratios and independent variables
| Both children and adults | 0.32 | p < .01 | 20 |
| Enteric bacteria | 0.45 | p < .01 | 20 |
| −0.44 | p < .01 | 30 | |
| MRSA | −0.48 | p < .01 | 29 |
| QREC | 0.37 | p < .01 | 10 |
| −0.31 | p < .01 | 41 | |
| Sulphonamides consumption | −0.28 | p < .01 | 20 |
| Macrolide consumption | −0.24 | p < .05 | 16 |
| Quinolones consumption | −0.22 | p < .05 | 12 |
| Northern Europe | −0.22 | p < .05 | 14 |
| Southern Europe | 0.24 | p < .05 | 15 |
*Number of cases in each category out of 88 cases total.